Nason, Martha C.

SARS-CoV-2 mRNA Vaccine Design Enabled by Prototype Pathogen Preparedness

Corbett, K. S., Edwards, D. K., Leist, S. R., Abiona, O. M., Boyoglu-Barnum, S., Gillespie, R. A., Himansu, S., Schäfer, A., Ziwawo, C. T., DiPiazza, A. T., et al. (2020) · Nature

SARS-CoV-2 and COVID-19 Researchvaccines and immunoinformatics approaches

Cited by 1,615

. Plasma levels of soluble CD14 independently predict mortality in HIV infection.

Sandler, N. G., Wand, H., Roque, A., Law, M., Nason, M. C., Nixon, D. E., Pedersen, C., Ruxrungtham, K., Lewin, S. R., Emery, S., et al. (2011) · The Journal of Infectious Diseases

HIV Research and TreatmentHIV-related health complications and treatments

Cited by 1,106

Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates

Corbett, K. S., Flynn, B., Foulds, K. E., Francica, J. R., Boyoglu-Barnum, S., Werner, A. P., Flach, B., O’Connell, S., Bock, K. W., Minai, M., et al. (2020) · New England Journal of Medicine

SARS-CoV-2 and COVID-19 ResearchAnimal Virus Infections Studies

Cited by 1,066

Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants

Pegu, A., O’Connell, S. E., Schmidt, S. D., O’Dell, S., Talana, C. A., Lai, L., Albert, J., Anderson, E., Bennett, H., Corbett, K. S., et al. (2021) · Science

SARS-CoV-2 and COVID-19 Researchvaccines and immunoinformatics approaches

Cited by 527

A proof of concept for structure-based vaccine design targeting RSV in humans

Crank, M. C., Ruckwardt, T. J., Chen, M., Morabito, K. M., Phung, E., Costner, P. J., Holman, L. A., Hickman, S. P., Berkowitz, N. M., Gordon, I. J., et al. (2019) · Science

Respiratory viral infections researchSARS-CoV-2 and COVID-19 Research

Cited by 333

Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates

Corbett, K. S., Nason, M. C., Flach, B., Gagne, M., O’Connell, S., Johnston, T. S., Shah, S. N., Edara, V. V., Floyd, K., Lai, L., et al. (2021) · Science

SARS-CoV-2 and COVID-19 ResearchAnimal Virus Infections Studies

Cited by 286

A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial

Martin, J. E., Louder, M. K., Holman, L. A., Gordon, I. J., Enama, M. E., Larkin, B. D., Andrews, C. A., Vogel, L., Koup, R. A., Roederer, M., et al. (2008) · Vaccine

SARS-CoV-2 and COVID-19 ResearchAnimal Virus Infections Studies

Cited by 267

Safety and tolerability of AAV8 delivery of a broadly neutralizing antibody in adults living with HIV: a phase 1, dose-escalation trial

Casazza, J. P., Cale, E. M., Narpala, S., Yamshchikov, G. V., Coates, E. E., Hendel, C. S., Novik, L., Holman, L. A., Widge, A. T., Apte, P., et al. (2022) · Nature Medicine

Virus-based gene therapy researchHIV Research and Treatment

Cited by 91

Immune Correlates of Protection by mRNA-1273 Immunization against SARS-CoV-2 Infection in Nonhuman Primates

Corbett, K. S., Nason, M. C., Flach, B., Gagne, M., O’ Connell, S., Johnston, T. S., Shah, S. N., Edara, V. V., Floyd, K., Lai, L., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory)

SARS-CoV-2 and COVID-19 ResearchAnimal Virus Infections Studies

Cited by 43